Sunday, March 01, 2015 6:03:44 PM
NanoLogix is pleased to announce that the Company, along with two of the world's leading biomedical research institutions as partners, has applied for funding from the Defense Threat Reduction Agency (DTRA), part of the U.S. Department of Defense, for further development of its N-Assay diagnostic for the Ebola virus.
This application was made under DTRA Proposal No: EBOLA-CBA-01-1-0165, Title: Diagnostics, Topic: CBA-01. Following the security and confidentiality requirements of DTRA, any further information will remain confidential until released by DTRA.
NanoLogix advises those interested that there is no guarantee of funding for any application made. The application was submitted after preliminary research by a separate group demonstrated valid proof of concept for rapid detection and identification of EBOV utilizing the N-Assay-V.
For further information on the ongoing efforts by the Department of Defense and DTRA on biological threats, you may follow the following links:
http://www.defense.gov/news/newsarticle.aspx?id=128260
DTRA is the U.S. Department of Defense’s official Combat Support Agency for countering weapons of mass destruction.
These links are provided as a public service for information and reference only and should not be construed in any way as an endorsement of NanoLogix by the DoD or DTRA.
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM